PARSIPPANY, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, announced it will ring the Nasdaq Closing Bell today in recognition of National Diabetes Awareness Month in November, celebrating the strength, well-being, and individuality of people living with diabetes. Advocacy and professional groups including the Association of Diabetes Care & Education Specialists (ADCES), Beyond Type 1, Beyond Type 2, Camp Nejeda, Children with Diabetes, Diab ...

文章核心观点 - 超微计算机公司(Supermicro)股价大跌20%,因为公司未明确说明何时将提交2024年度年报,这是其遵守纳斯达克规则的必要条件 [1][2] - 摩根大通分析师将公司目标价下调超过50%,原因是公司业务更新和财报电话会议中存在多个风险因素 [2] - 超微公司被要求在11月16日之前提交年报,否则将面临退市风险 [2] 公司情况总结 - 超微公司之前曾收到纳斯达克的警告函,称其未能及时提交报告,公司计划申请延期 [2] - 公司的审计公司安永会计师事务所已经辞任,公司正在积极寻找新的审计公司 [3] - 公司董事会特别委员会未发现有欺诈或不当行为,但分析师认为审计师的行为与特别委员会的结论存在矛盾,增加了困惑 [3] - 公司股价今年下跌约20%,但仍远低于2024年初的120美元以上的高位 [3]

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 500 points on Wednesday.The Dow traded up 3.45% to 43,678.43 while the NASDAQ rose 2.84% to 18,963.41. The S&P 500 also rose, gaining, 2.44% to 5,923.85.Check This Out: How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 EarningsLeading and Lagging SectorsFinancial shares surged by 5.9% on Tuesday.In trading on Tuesday, real estate shares fell by 3.3%.Top HeadlineJohnson Controls International plc JCI repor ...

PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted immunotherapeutic drugs, today announced the pricing of an underwritten public offering of 1,111,111 shares of common stock (or pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and common warrants to purchase up to an aggregate of 2,222,222 shares of common stock. Each share of commo ...

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.October 2024 was a fairly quiet month on Wall Street. The major market indices stayed within 3% of their starting scores throughout the month despite economic uncertainty and a nerve-wracking election cycle.But the stock market never sleeps, especially in its more growth-oriented and volatile sectors. Four of the 101 stocks in the NASDAQ-100 ...

NEW YORK and TOKYO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and data consulting services company based in Tokyo, announced today that it has received written notice from the Nasdaq Stock Market LLC that the Company demonstrated compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and that the Company is therefore in compliance ...

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing RulesNovember 05, 2024 8:30 AM EST | Source: InMed PharmaceuticalsVancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, toda ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode’s request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...